Details for Patent: 8,158,580

Summary for Patent: 8,158,580

Title:	Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Abstract:	Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.
Inventor(s):	J. Kevin Judice, Jeng-Pyng Shaw, YongQi Mu, Michael W. Conner, John L. Pace
Assignee:	Cumberland Pharmaceuticals Inc
Application Number:	US12/431,940
Patent Claim Types: see list of patent claims	Composition;

United States Patent 8,158,580 (Vancomycin Lipidated Derivative + Cyclodextrin): Claim Scope, Patent Landscape, and Generic Risk

Executive summary: U.S. Patent 8,158,580 claims a pharmaceutical composition defined by two mandatory components: (i) a lipidated vancomycin derivative (or its pharmaceutically acceptable salt) and (ii) a specific cyclodextrin class limited to hydroxypropyl-β-cyclodextrin or sulfobutyl ether β-cyclodextrin. The patent’s scope is composition-level (not a method-of-treatment claim in the provided set), and enforcement risk for generic or follow-on formulations centers on whether a competitor’s drug product includes both elements and uses either of the two cyclodextrins. Litigation and portfolio impact depend on whether other patents cover the specific lipidated vancomycin derivative, its manufacturing, and drug-product formulation beyond cyclodextrins.

---

What does U.S. Patent 8,158,580 claim: scope of “lipidated vancomycin derivative” + cyclodextrin?

Core claim construct (independent claim 1):
A pharmaceutical composition comprising:

1. A lipidated vancomycin derivative (or pharmaceutically acceptable salt), and
2. A cyclodextrin selected from:
   • hydroxypropyl-β-cyclodextrin (HP-β-CD), or
   • sulfobutyl ether β-cyclodextrin (SBE-β-CD).

Immediate scope takeaways:

• Both ingredients are required. A product that uses lipidated vancomycin derivative but uses a different solubilizer/cyclodextrin not listed in claim 1 is outside this claim language.
• Both ingredient types are broad on the “lipidated vancomycin derivative” axis. “Lipidated” is claim-language expansive unless the specification constrains it to particular lipid moieties (chain length, linkage chemistry, degree of substitution) or particular vancomycin derivatives.
• Cyclodextrin selection is narrow and enumerated. Only two cyclodextrins are within the independent claim’s explicit selection set, which creates a clear design-around lever.

How narrow is the cyclodextrin limitation in claim 1?

Claim 1 explicitly limits the cyclodextrin to:

• Hydroxypropyl-β-cyclodextrin (HP-β-CD)
• Sulfobutyl ether β-cyclodextrin (SBE-β-CD)

This language can matter in litigation if a competitor uses:

• β-cyclodextrin without substitution (not in claim 1),
• methyl-β-cyclodextrin (not in claim 1),
• randomly substituted β-cyclodextrin derivatives not matching HP or SBE substitution definitions,
• mixed cyclodextrin systems where either HP-β-CD or SBE-β-CD is present.

If a product includes only one of these cyclodextrins, claim 1 is still satisfied because the claim is “selected from,” not “consisting of.” If a product contains both HP-β-CD and SBE-β-CD, claim 1 is still satisfied.

What do dependent claims 2 and 3 add?

• Claim 2: cyclodextrin is hydroxypropyl-β-cyclodextrin.
• Claim 3: cyclodextrin is sulfobutyl ether β-cyclodextrin.

These dependent claims do not expand scope; they specify which member of the enumerated cyclodextrin set is used. They increase enforceability across a competitor’s formulation variants if the competitor switches between HP-β-CD and SBE-β-CD.

---

How might courts construe “lipidated vancomycin derivative” for U.S. Patent 8,158,580?

Claim language issue: “lipidated vancomycin derivative” is a functional/structural descriptor that can be construed using:

• the ordinary meaning of “lipidated” in the art,
• the specification for definition or examples of lipid moieties and linkage,
• prosecution history for any narrowing definitions,
• expert testimony tied to the disclosed chemical structures.

Enforcement leverage: If the patent specification defines “lipidated vancomycin derivative” narrowly to specific derivatives (for example, defined lipid chains or defined chemical linkage to vancomycin), then claim breadth will be constrained. If it defines broadly (for example, any lipid chain with a defined range and any acceptable attachment pattern), competitors face higher infringement risk.

Litigation friction points (what typically becomes claim-construction battlegrounds):

• Whether “lipidated” requires a covalent lipid attachment versus noncovalent complexation.
• Whether “derivative” includes chemically modified variants beyond the lipid group (for example, additional substitutions on vancomycin).
• Whether salt forms change the “lipidated derivative” analysis (claim language includes “pharmaceutically acceptable salt thereof,” so salts are generally within claim 1 if the underlying lipidated derivative is present).

---

What formulation elements are NOT claimed in U.S. Patent 8,158,580?

Based on the provided claim set (claims 1–3 only), the claims do not explicitly recite:

• dosage form (e.g., vial, infusion solution, lyophilized powder),
• concentration ranges,
• excipients other than cyclodextrin,
• route of administration,
• therapeutic indication or method-of-use.

This is important because:

• A competitor could potentially argue their product is outside the claim if it avoids the combination of “lipidated vancomycin derivative” and “HP-β-CD or SBE-β-CD.”
• If a competitor contains the claimed combination, other excipients do not remove infringement for a composition claim, assuming the rest of the claim elements are met.

---

How many cyclodextrin alternatives can design around U.S. Patent 8,158,580?

Direct design-around categories:

1. Use a lipidated vancomycin derivative + a cyclodextrin other than HP-β-CD or SBE-β-CD, such as:
   • β-cyclodextrin (unsubstituted),
   • methyl-β-cyclodextrin,
   • dimethyl-β-cyclodextrin,
   • other substituted β-cyclodextrins not matching claim wording.
2. Avoid cyclodextrin entirely using alternative solubilization systems (surfactants, polymers, liposomes), if doing so avoids the enumerated cyclodextrins.

Combination design-around principle:
If the competitor’s product still uses HP-β-CD or SBE-β-CD, it keeps risk against claim 1. The cleanest textual avoidance is swapping the cyclodextrin outside the two enumerated types.

---

What other patents typically sit around U.S. Patent 8,158,580: lipidated vancomycin derivative, drug product, and manufacturing?

Without access to the full patent family data inside this prompt, the actionable landscape analysis must be framed as a portfolio map pattern commonly present around composition claims like this:

1) “Core active” patents (structure-defining)

These typically cover:

• the specific lipidated vancomycin derivative chemical entities (specific lipid moiety and attachment),
• preparation of the lipidated derivative (chemical synthesis steps),
• salt/polymorph definitions.

Why they matter:
If U.S. 8,158,580 covers a broad “lipidated vancomycin derivative” catch-all, other patents in the family can still block development of a specific derivative even if a cyclodextrin design-around is used.

2) Formulation and solubilizer patents

These commonly cover:

• combinations with HP-β-CD, SBE-β-CD, or other cyclodextrins,
• concentration ranges,
• buffering systems,
• isotonicity agents,
• particle size control for suspensions.

Why they matter:
Even if a competitor avoids HP-β-CD/SBE-β-CD, a formulation patent covering another solubilizer system may still present risk.

3) Method-of-use and clinical regimen patents

These cover:

• indication(s),
• dosing frequency,
• treatment for resistant Gram-positive infections,
• use in specific populations.

Why they matter:
A composition carve-out does not remove method-of-use risk if the competitor’s product is intended for the same claimed uses.

4) Manufacturing and process patents

These cover:

• conjugation/synthesis routes,
• purification strategies,
• sterile filling and lyophilization,
• stability and degradation control.

Why they matter:
Process patents can block manufacturing even if a formulation design-around is achieved.

---

What generic entry risks exist for a product practicing U.S. Patent 8,158,580’s composition?

Primary infringement pathway for a competitor’s formulation:
For a composition claim, infringement depends largely on:

• presence of the lipidated vancomycin derivative,
• presence of the cyclodextrin within the claimed set,
• and whether the accused product “comprises” those elements.

Paragraph IV / FDA pathway implications

For a small-molecule IV antibiotic, generics typically seek an Abbreviated New Drug Application (ANDA). For complex biologic-like constructs, there can be different regulatory tracks, but the infringement question remains composition-based.

Practical risk framing:

• If an applicant files an ANDA with the same lipidated derivative and uses HP-β-CD or SBE-β-CD, the U.S. 8,158,580 claim 1 is a straightforward infringement target.
• If the applicant substitutes the cyclodextrin outside the claim set, the infringement theory weakens on claim 1 but may shift to other patents in the estate.

Litigation leverage

A patentee can pursue:

• product-based infringement (composition identity),
• inducement/contributory infringement depending on evidence of knowledge and instruction,
• preliminary injunction if likelihood of success and irreparable harm are established.

U.S. Patent 8,158,580 is composition-defined, which typically supports product identity arguments when analytical evidence exists (HPLC/LC-MS for active, NMR or chromatography for excipient identity/quantity).

---

How does U.S. Patent 8,158,580 compare with typical cyclodextrin-formulation claim patterns?

Unlike broad solubilizer patents, the cyclodextrin choice here is enumerated. Many formulation patents use “cyclodextrin” broadly, or cover multiple substituted β-cyclodextrins with ranges. Claim 1 here restricts to:

• HP-β-CD, and
• SBE-β-CD.

Commercial implication:
This can reduce the number of viable design-arounds in a purely “solubilizer swap” sense for products needing those two cyclodextrins for solubility or stability. But it provides a clear off-ramp if other solubilizers can preserve stability and bioavailability.

---

What is the Orange Book status of U.S. Patent 8,158,580?

No answer provided. The prompt contains only claim text and does not provide the listed drug name, application number, NDA/ANDA/BLA link, or Orange Book identifiers. Without that, a complete and accurate Orange Book status mapping cannot be produced.

---

What patent-expiration and exclusivity timelines apply to U.S. Patent 8,158,580?

No answer provided. The prompt does not provide filing date, priority date, PTA, terminal disclaimer status, or family member data. Without those, expiration timing cannot be calculated accurately.

---

What patent litigation affects U.S. Patent 8,158,580?

No answer provided. The prompt does not provide litigation captions, parties, district, case numbers, or asserted claims beyond the claim list provided. Without those, a complete and accurate litigation landscape cannot be produced.

---

Which companies are challenging or licensing lipidated vancomycin derivative/cyclodextrin formulations?

No answer provided. Company identifiers and challenge/settlement history require external docket and transaction data not present in the prompt.

---

Key Takeaways

1. Claim 1 is a binary composition gate: it requires a lipidated vancomycin derivative plus either HP-β-CD or SBE-β-CD.
2. Dependent claims 2–3 add formulation specificity for each of the two enumerated cyclodextrins, strengthening enforceability across formulation variants.
3. Design-around is most direct via cyclodextrin substitution: using lipidated vancomycin derivative with a cyclodextrin outside HP-β-CD/SBE-β-CD is the cleanest textual avoidance based on the provided claims.
4. Enforcement breadth likely turns on how the specification defines “lipidated vancomycin derivative.” The active-definition construal can materially expand or contract infringement risk.
5. Freedom to operate usually requires a broader estate review for active-structure patents, formulation patents, and process patents that may block development even if cyclodextrin is swapped.

---

FAQs

1. Can a product using both HP-β-CD and SBE-β-CD infringe claim 1?
   Yes, if it contains a lipidated vancomycin derivative and both are present, claim 1’s “selected from” limitation is satisfied.

2. Does using a different cyclodextrin avoid infringement of U.S. Patent 8,158,580 claim 1?
   Textually, yes, if neither HP-β-CD nor SBE-β-CD is present and the competitor uses only non-enumerated cyclodextrins.

3. Are salt forms covered under claim 1?
   Yes. The claim expressly includes “pharmaceutically-acceptable salt thereof” for the lipidated vancomycin derivative.

4. Does U.S. Patent 8,158,580 cover dosing or therapeutic method steps?
   Not based on claims 1–3 provided. The provided claims are composition claims.

5. What is the most important analytical evidence in an infringement case for this patent?
   Chemical confirmation of the lipidated vancomycin derivative identity and analytical confirmation that HP-β-CD or SBE-β-CD is present in the accused composition.

---

References

1. U.S. Patent 8,158,580 (claim text provided in prompt).

Drugs Protected by US Patent 8,158,580

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,158,580

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1292612		C300507	Netherlands
European Patent Office	1292612		CA 2011 00033	Denmark
European Patent Office	1292612		91908	Luxembourg
European Patent Office	1292612		PA2012002	Lithuania
European Patent Office	1292612		1190036-2	Sweden